로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IGFBP-1

IGFBP-1

요약

Name:Insulin-like growth factor I
Target Synonym:IGF-I,Insulin-Like Growth Factor IB,Insulin-Like Growth Factor I,Somatomedin C,IGFI,IGF1A,IGF,IBP1,MGF,Mechan* growth factor,IGF1,Insulin Like Growth Factor 1,Insulin-Like Growth Factor 1 (Somatomedin C),Somatomedin-C
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Phase 3 Clinical

제품 리스트 구매

제품 상태별:
제품 유형별 :
종별:
태그별:
결합물별:
제품번호 제품 설명 구조 순도 특징
IG1-H52H3 Human Human IGFBP-1 Protein, His Tag (MALS verified)
IG1-H52H3-structure
IG1-H52H3-sds

일부의 생물활성 데이터

IG1-H52H3-MALS-HPLC
IGFBP-1 MALS images

The purity of Human IGFBP-1 Protein, His Tag (Cat. No. IG1-H52H3) is more than 90% and the molecular weight of this protein is around 22-32 kDa verified by SEC-MALS.

IG1-H52H3-ELISA
 IGFBP-1 ELISA

Immobilized Human IGF-I, Fc Tag at 5 μg/mL (100 μL/well) can bind Human IGFBP-1 Protein, His Tag (Cat. No. IG1-H52H3) with a linear range of 0.01-0.156 μg/mL (QC tested).

Synonym Name

IGFBP1,PP12,IBP1

Background

Insulin-like growth factor-binding protein 1 (IGFBP1) is also known as placental protein 12 (PP12), which contains oneIGFBP N-terminal domain and one thyroglobulin type-1 domain. IGFBP1 can bindd both insulin-like growth factors (IGFs) I and II and circulates in the plasma. Binding of IGFBP1 can prolongd the half-life of the IGFs and alterd their interaction with cell surface receptors. Furthermore, IGFBP1 can promote cell migration. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
NA-931 NA-931 Phase 3 Clinical Biomed Industries Inc Weight Loss; Diabetes Mellitus, Type 2; Body Weight Changes; Body Weight; Obesity; Overweight; Diabetes Mellitus Details
ACT-01 ACT-01; OCS-05; BN-201; G-79 Phase 2 Clinical Promius Pharma Keratosis, Actinic; Optic Neuritis; Demyelinating Diseases Details
Xentuzumab BI-836845 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NA-941 NA-941 Phase 2 Clinical Biomed Industries Inc Metabolic Dysfunction-Associated Steatotic Liver Disease Details
VMB-100 VMB-100 Phase 2 Clinical Touchlight Genetics Ltd, Versameb AG Urinary Incontinence, Stress Details
Pasireotide long-acting formulation (Camurus) CAM-4071 Phase 1 Clinical Camurus Ab Endocrine System Diseases Details
TE-8214 TE-8214 Phase 1 Clinical Immunwork Inc Acromegaly; Neuroendocrine Tumors Details

This web search service is supported by Google Inc.

totop